Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Narcolepsy

Therapeutic area intelligence for Narcolepsy with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
7
Catalysts
0
Companies
4

Companies

Centessa Pharmaceuticals →
Lupin →
MSN Laboratories →
Novitium Pharma →

Assets

Alkermes →
Cleminorexton →
FDA →
Northwestern →
Orzeyful →
Pitolisant →

Recent signals(7)

RegulatoryAugust 19, 2026

Lupin Limited's Pitolisant ANDA218846 Receives Approval Status

Lupin Limited's ANDA218846 for Pitolisant has received an Approval Pending (AP) status from the FDA.

RegulatoryAugust 19, 2026

FDA grants approval for Pitolisant ANDA218873 by MSN Laboratories

The FDA has granted approval for the Abbreviated New Drug Application (ANDA218873) for Pitolisant submitted by MSN Laboratories. This approval allows MSN Laboratories to market a generic version of Pitolisant, indicated for the treatment of narcolepsy.

RegulatoryAugust 6, 2026

FDA Approves Orzeyful for Narcolepsy Type 1 Treatment

The FDA has approved Orzeyful (oveporexton) tablets for treating the full range of narcolepsy type 1 symptoms in adults.

CompetitiveAugust 4, 2026

ALKS 2680 Shows Promise in Reducing Sleepiness and Cataplexy in Narcolepsy Type 1

A study is underway to evaluate the safety and effectiveness of ALKS 2680 in patients with Narcolepsy Type 1.

StrategyJuly 24, 2026

FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma

The FDA has granted approval for Pitolisant Hydrochloride under ANDA218495 submitted by Novitium Pharma.

ClinicalJuly 14, 2026

Cleminorexton Study for Narcolepsy Type 1 and Type 2 Initiated by Centessa Pharmaceuticals

A clinical trial is underway to evaluate the safety and tolerability of cleminorexton in patients with Narcolepsy Type 1 and Type 2.

ClinicalJuly 6, 2026

Northwestern University Trials Behavioral Treatments for Narcolepsy-Related Nightmares

A clinical trial is underway to evaluate the effectiveness of imagery rehearsal therapy and targeted dream control for treating nightmares in narcolepsy patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.